Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.62 |
| ▸ | CPT2 | P23786 | 1/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1831810 | 1.00 | TDP1 (0.62) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL1833933 | 1.00 | TDP1 (0.62) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL14360000 | 0.95 | TDP1 (0.58) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL27628078 | 0.95 | TDP1 (0.58) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL14359845 | 0.93 | TDP1 (0.54) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL7864001 | 0.91 | GPR84 (0.58) | TDP1FFAR1CPT2TSHRGPR84 | |
| SCHEMBL1116137 | 0.91 | GPR84 (0.58) | TDP1FFAR1CPT2TSHRGPR84 | |
| SCHEMBL3280282 | 0.91 | TDP1 (0.54) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL6696708 | 0.91 | GPR84 (0.54) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL1116131 | 0.91 | GPR84 (0.58) | TDP1FFAR1CPT2TSHRGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0988274-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROMEX LTD (IL) | 2009-05-20 | — | — | EP | claimed |
| EP-0988274-A4 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2000-10-18 | — | — | EP | claimed |
| EP-0988274-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-03-29 | — | — | EP | claimed |
| WO-1998030530-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | claimed |
| EP-2112134-B1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | SYNDROMEX LTD (IL) | 2013-10-30 | — | — | EP | disclosed |
| EP-2112134-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Syndromex Ltd. (IL) | 2009-10-28 | — | — | EP | disclosed |
| EP-0988274-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROMEX LTD (IL) | 2009-05-20 | — | — | EP | disclosed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1651205-A1 | METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISEASES WITH A STATIN AND ETHER | Warner-Lambert Company LLC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009431-A1 | METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISEASES WITH A STATIN AND ETHER | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040132818-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | SYNDROMEX LTD. (IL) | 2004-07-08 | — | — | US | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-20020049345-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | SYNDROMEX LTD. (IL) | 2002-04-25 | — | — | US | disclosed |
| US-6284903-B1 | TREATING HYPERLIPIDEMIA, OBESITY AND IMPAIRED GLUCOSE TOLERANCE/NONINSULIN DEPENDENT DIABETES MELLITUS WITHOUT ADVERSELY AFFECTING ENERGY METABOLISM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-09-04 | — | — | US | disclosed |
| EP-0988274-A4 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2000-10-18 | — | — | EP | disclosed |
| EP-0988274-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998030530-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | TDP1 2229/4885FFAR1 144/4885CPT2 360/4885 |
| US-20040132818-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | CYP2F1, QPCT, CBR3 | TDP1 4809/4885FFAR1 211/4885CPT2 1546/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | TDP1 3613/4885FFAR1 1371/4885CPT2 714/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | TDP1 3202/4885FFAR1 265/4885CPT2 434/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | TDP1 4216/4885FFAR1 449/4885CPT2 1268/4885 |
| US-20020049345-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | CYP2F1, QPCT, CYP2D6 | TDP1 4807/4885FFAR1 200/4885CPT2 1580/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | TDP1 3787/4885FFAR1 96/4885CPT2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.